BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day

BrainsWay Ltd. (NASDAQ & TASE: BWAY), a prominent player in noninvasive brain stimulation technologies, announced its upcoming participation in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day, taking place on February 26, 2026, in New York, NY. Interested parties are advised to reach out to their Citi representatives to schedule meetings.

Founded in 2003 and with operations in both the United States and Israel, BrainsWay is noted for its innovative Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, which is aimed at treating various mental health disorders. The company has made significant strides in neuroscience, positioning itself as a leader through its proprietary technology that enhances patient care. BrainsWay is unique in being the first and only TMS company holding FDA clearances for three distinct indications, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. These indications are supported by robust clinical studies affirming their efficacy.

In addition to its current offerings, BrainsWay is committed to advancing its clinical research, with additional trials exploring the applications of Deep TMS across multiple psychiatric, neurological, and addiction disorders. The company is dedicated to enhancing global awareness and access to its innovative treatments, striving to transform the lives of individuals dealing with complex mental health challenges.

For further information and updates related to BrainsWay and its efforts in neurostimulation, stakeholders can visit the company's official website at www.brainsway.com. For investor inquiries, Ido Marom, Chief Financial Officer, can be contacted directly, along with Brian Ritchie at LifeSci Advisors for investor relations-related inquiries.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) is positioned as a pivotal player in the rapidly evolving field of neurostimulation therapies, particularly given its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform. Participating in the Citi 2026 Unplugged MedTech and Life Sciences Access Day offers BrainsWay substantial visibility and potential engagement with investors that could significantly impact its market perception and growth trajectory.

The company's leading position is underscored by its FDA-clearance for three distinct indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Each of these conditions addresses substantial market needs, particularly with the rising incidence of mental health disorders globally. BrainsWay's commitment to clinical research bolsters its reputation, as ongoing trials in various psychiatric and neurological disorders may yield further applications and enhance its product portfolio.

Investors should consider the potential implications of ongoing and future clinical trials, as successful outcomes can lead to broadened market access and increased revenues. The focus on expanding the understanding and acceptance of Deep TMS within the mental health community and healthcare providers is crucial. As awareness grows, BrainsWay could see a significant uptick in adoption rates, positioning itself as a leader in noninvasive treatments.

However, market participation is not without risks. The competitive landscape in neurostimulation is evolving, and emerging technologies may challenge BrainsWay's current market position. Therefore, a close watch on competitor movements and regulatory developments is warranted.

In summary, BrainsWay demonstrates a compelling investment opportunity, particularly for investors focused on MedTech and mental health interventions. Attending the Citi 2026 event represents not only an opportunity for investor engagement but also a chance for BrainsWay to refine its strategic vision in a growing market, making it a stock to watch in the coming years.